Clearside Biomedical (NASDAQ:CLSD – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
Several other analysts have also recently commented on the company. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a report on Monday, October 14th. Needham & Company LLC upped their target price on Clearside Biomedical from $4.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Oppenheimer assumed coverage on Clearside Biomedical in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $5.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Clearside Biomedical in a research note on Tuesday, August 27th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.17.
View Our Latest Stock Report on Clearside Biomedical
Clearside Biomedical Price Performance
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.25 million. During the same quarter in the previous year, the company posted ($0.15) EPS. Equities research analysts anticipate that Clearside Biomedical will post -0.56 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Clearside Biomedical
A number of institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in shares of Clearside Biomedical in the first quarter worth about $49,000. International Assets Investment Management LLC purchased a new position in Clearside Biomedical in the first quarter valued at about $57,000. XTX Topco Ltd boosted its holdings in Clearside Biomedical by 172.2% in the second quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock valued at $71,000 after purchasing an additional 34,359 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Clearside Biomedical during the second quarter valued at approximately $368,000. Finally, Renaissance Technologies LLC raised its stake in Clearside Biomedical by 6.6% during the second quarter. Renaissance Technologies LLC now owns 582,689 shares of the company’s stock valued at $757,000 after buying an additional 35,900 shares in the last quarter. Hedge funds and other institutional investors own 18.75% of the company’s stock.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Further Reading
- Five stocks we like better than Clearside Biomedical
- How to Use the MarketBeat Stock Screener
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Consumer Staples Stocks, Explained
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What are earnings reports?
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.